Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin in Immunocompromised Children With Fever and Neutropenia
NCT00056381Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2003
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of anidulafungin in invasive fungal infection (IFI) (4 arms), sponsored by Pfizer. Primary endpoints: Safety and Tolerability at 28 days and Pharmacokinetics at Day 5. Started Jul 2003; status: completed.
02
Drugs
anidulafungin
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00056381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056381.